Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this trial is to lower the morbidity rate in elderly patients affected with systemic necrotizing vasculitides, by reducing mortality and improving global outcome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Azathioprine; Cyclophosphamide; Methotrexate; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Mycophenolate mofetil; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prednisone

Criteria

Inclusion Criteria:

• Newly diagnosed WG, MPA, PAN without HBV infection, or CSS

• Patients can be still be enrolled within 1 month after starting corticosteroids if prescribed according to protocol.

• within or after the 65th of anniversary

• Age ≥ 65 years

Exclusion Criteria:

• Any cytotoxic drug within previous year

• Co-existence of another systemic autoimmune disease, e.g., SLE, RA

• Virus-associated vasculitides

• HIV positivity

• Malignancy (usually excluded unless approved by the trial coordinator)

• Age < 65 years

• Inability to give informed consent